Hydrogen gas therapy as an emerging and promising therapy strategy has overwhelming advantages especially in bio-safety compared with other gas therapy routes, but is facing a great challenge in the long-term, highly-concentrated, deeply-seated disease site-specific administration of hydrogen gas, owing to its low solubility, high but aimless diffusibility in vivo. Herein, we propose to construct an ammonia borane-loaded mesoporous silica nanomedicine (AB@MSN) to realize the intratumoral high-payload delivery and in situ acid-controlled release of hydrogen gas. The constructed AB@MSN nanomedicine has a superhigh H2 loading capacity (130.6 mg/g, more than 1370 times higher than that of the traditional H2@liposome nanomedicine) and a highly acid-responsive sustained release behavior, exhibiting high anticancer efficacies and high bio-safety in vitro and in vivo. The proposed nanomedicine-based strategy opens a new window for precision high-efficacy hydrogen therapy.
- Controlled release
- Drug delivery
- Hydrogen therapy
- Mesoporous silica nanoparticles
FingerprintDive into the research topics of 'Intratumoral high-payload delivery and acid-responsive release of H<sub>2</sub> for efficient cancer therapy using the ammonia borane-loaded mesoporous silica nanomedicine'. Together they form a unique fingerprint.
Technological Platform Physical Chemistry and characterization
Facility/equipment: Technological Platform